• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy & clinical immunology international: official organ of the International Association of Allergology and Clinical Immunology >Mometasone Furoate Nasal Spray in Seasonal Allergic Rhinitis: Effective in Relieving Ocular Symptoms
【24h】

Mometasone Furoate Nasal Spray in Seasonal Allergic Rhinitis: Effective in Relieving Ocular Symptoms

机译：莫米松糠醛酸盐鼻腔喷雾剂治疗季节性变应性鼻炎：有效缓解眼部症状

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Mometasone furoate nasal spray (MFNS) is effective for preventing and treating nasal symptoms in seasonal allergic rhinitis (SAR). Its effects on ocular symptoms have not been investigated. This retrospective analysis examined the effects of MFNS on ocular symptoms in subjects with SAR. Methods/Data base: Ocular symptom data were pooled and analyzed from four randomized, double-blind studies comparing MFNS 200 mcg once daily (n = 494) with placebo (n = 497). Subject-reported ocular itching, redness, and tearing were recorded at baseline and twice daily throughout treatment on a scale of 0 (none) to 3 (severe). Total ocular symptom score (TOSS) was defined as the combined 2-week average symptom scores. Results: MFNS produced a statistically greater reduction in TOSS from baseline as compared to placebo (-1.33 vs. -0.94, p < 0.05). Likewise, mean 2-week reductions in individual symptoms were significantly improved with MFNS (p < 0.05 for each symptom). In subjects with TOSS >= 4 at baseline, MFNS recipients (n = 298) reported a significantly greater reduction in TOSS as compared to placebo recipients (n = 304; -1.97 vs. -1.51, p < 0.05), with statistically significant benefits also observed in individual ocular symptoms (p < 0.05 for each symptom). Conclusions: MFNS has a beneficial effect on ocular symptoms, in addition to its established effects on nasal symptoms, in subjects with SAR.
机译：背景：糠酸莫米松鼻喷剂（MFNS）可有效预防和治疗季节性变应性鼻炎（SAR）的鼻部症状。尚未研究其对眼部症状的影响。这项回顾性分析检查了MFNS对SAR受试者眼部症状的影响。方法/数据库：收集并分析四项随机双盲研究的眼部症状数据，将每日两次MFNS 200 mcg（n = 494）与安慰剂（n = 497）进行比较。基线时记录受试者报告的眼部瘙痒，发红和流泪，在整个治疗过程中每天两次，以0（无）至3（严重）的等级记录。总眼症状评分（TOSS）定义为2周平均症状评分总和。结果：与安慰剂相比，MFNS与基线相比TOSS的统计学降低更大（-1.33 vs.-0.94，p <0.05）。同样，使用MFNS可以显着改善平均2周的个体症状缓解（每种症状p <0.05）。在基线时TOSS> = 4的受试者中，MFNS接受者（n = 298）报告的TOSS降低量明显高于安慰剂接受者（n = 304; -1.97 vs.-1.51，p <0.05），具有统计学上的显着益处在个别眼部症状中也观察到（每种症状p <0.05）。结论：MFNS除对鼻部症状已确立的作用外，对SAR受试者还具有对眼部症状的有益作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号